Kenneth S. Abramowitz
Managing General Partner
Kenneth S. Abramowitz is a co-founder and Managing General Partner of NGN Capital. He joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry. Beginning July 2003, he transitioned to Senior Advisor at Carlyle in order to devote the time necessary to create a dedicated healthcare fund on behalf of Carlyle. Prior to joining Carlyle, Mr. Abramowitz worked as an Analyst at Sanford C. Bernstein & Co. where he covered the medical-supply, hospital-management and HMO industries for 23 years, after which he was an EGS Securities Healthcare Fund Manager. He was voted top hospital supply and/or service analyst on the Institutional Investor Magazine "All-America Research Team" during 15 out of 20 years between 1980-2000 and made “The Team” for both healthcare services and medical supplies for 9 years since 1987.
John R. Costantino
Managing General Partner
John R. Costantino is a Managing General Partner of NGN Capital LLC. He is a lawyer and CPA. John was Managing Tax Partner in the New York office of Touché Ross & Co. and then President of Integrated Resources Acquisition Corporation. He was Chief Operating Officer of Conair Corporation, a large household and personal care company. He was a founding partner of a private equity fund, merchant banking group and co-founded several biotech and medical device companies.
He presently serves as the Independent Chairman of a State Street Coproration fund group which was formerly the General Electric Company's family of mutual funds. He has served and continues to serve on a number of public and private company boards of directors as well as the Boards of a number of charitable organization.
Managing General Partner
Dr. Peter Johann is a Managing General Partner of NGN Capital. He joined from Boehringer Ingelheim where he was the Division Head of Corporate Development. Dr. Johann has established a worldwide network in the Biotech and Pharmaceutical Industry. His responsibilities at Boehringer Ingelheim included strategic planning, strategic projects, M&A, business development and licensing. He identified and evaluated several licensing, M&A and co-promotion deals. Prior to this Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim where he was Head of Business Development and Marketing Molecular Medicine.
Alexander Cuomo, Chief Financial Officer
Alexander Cuomo, is the Chief Financial Officer of NGN Capital. Mr. Cuomo joined NGN in 2008. Prior to joining NGN, he practiced accounting and tax matters primarily for high-net worth individuals, family offices, partnerships and corporations. Mr. Cuomo is responsible for financial reporting, tax compliance, and audit compliance for both the U.S. and German Funds. His other responsibilities include portfolio company valuation, internal strategy and analytics, budgeting, and investor relations. Alexander completed his undergraduate degree at Ithaca College and his Master of Science in Finance from the Lubin School of Business at Pace University in New York City.
William J. Gedale , Senior Advisor
William J. Gedale is a Senior Advisor and co-founder of NGN Capital. He has been in the investment business since 1965. Mr. Gedale joined NGN from Mount Everest Advisors, which he founded in 1996. He has served as an investment advisor to individuals and as a full time consultant to Warburg-Pincus Capital Management, the world's largest venture capital firm, between 1999 and 2001. In this capacity, he initiated the $140 million dollar financing of ZymoGenetics. He also helped arrange the $350 million funding by Sandoz (Novartis) of the Scripps Research Institute and the $40 million funding of the Neuroscience Institute of La Jolla, California (of which he is a trustee). Before founding Mount Everest Advisors he was a Managing Director at John W. Bristol & Co. in 1995. Before this, as of 1989, Mr. Gedale was President & Chief Executive Officer of General American Investors, which he had joined in 1969. He is currently Chairman of Promosome. He has been a director of Gamco (Gabelli Holding), General American Investors, Allied Clinical Laboratories, U.S. Home Health Care, Unilab Corporation, and BioReliance Corporation. William Gedale holds an M.B.A. from New York University, a J.D. from Fordham Law School, and an A.B. from Syracuse University. He currently serves on the Board of Directors of PIN Pharma and previously served on the Board of Directors of KIKA Medical Inc., acquired by Merge Healthcare, and BioArray Solutions, acquired by Immucor; Unilab acquired by Kelso; Allied Clinical Labs acquired by Labcorp; Bioreliance acquired by Sigma-Aldrich; Gamco; and General American Investors where he served as President & Chief Executive Officer.
Kenneth J. Gorelick , Venture Partner
Kenneth J. Gorelick, M.D. has 30 years of experience in the development of drugs, biologics and medical devices in the human health care sector. He is currently a consultant to the biopharmaceutical industry. Dr. Gorelick has expertise with numerous approvals of BLAs, NDAs and MAAs. He has held the position of Vice President of Global Clinical Research and Development at Dupont Merck Research Laboratories, Inc. a research-driven pharmaceutical company. He was also Vice President of Drug Development and Chief Medical Officer at Genelabs, a biotechnology company focused on infectious and autoimmune disease. He currently serves as Chief Medical Officer for PIN Pharma and chairs the Program Advisory Board for Asahi Kasei Pharma America, and is a Director of Neurotrope Bioscience, among others. He has a B.S. from the State University of New York at Buffalo, a M.D. from Weill Cornell Medical College,and received postdoctoral training at St. Louis University and Stanford University, where he was Clinical Associate Professor of Medicine until 2000. Dr. Gorelick is Board Certified in Internal Medicine and Pulmonary Diseases and is a Fellow of the American College of Chest Physicians.